THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS

a genome editing and genome technology, applied in the field of therapeutic use of genome editing with crispr/cas systems, can solve the problems of only 2%-4% efficiency of allele targeting in human stem cells, and achieve the effect of efficiently effectively deleting target polynucleotide sequences

Pending Publication Date: 2018-10-11
PRESIDENT & FELLOWS OF HARVARD COLLEGE +1
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a method for using CRISPR / Cas systems to efficiently target and edit genes in primary somatic cells, such as human blood cells and T cells. This is done through a multiple guide strategy, which uses two or more ribonucleic acids to direct Cas protein to a specific target sequence. This approach resulted in mutant cells with a higher efficiency of up to 80%. The patent also provides methods for delivering CRISPR / Cas systems to human stem cells and identifying useful RNA guide sequences for targeting specific genes. Finally, the invention provides a method for treating HIV infection by altering the target polynucleotide sequence in cells using CRISPR / Cas systems. Overall, this patent presents important advancements in the field of gene editing and holds potential therapeutic applications.

Problems solved by technology

Thus, CRISPR / Cas systems could be useful tools for therapeutic applications, but unfortunately prior published reports have demonstrated an efficiency of allele targeting of only 2%-4% in human stem cells (Mali et al., Science 339:823-826 (2013)).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS
  • THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS
  • THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0289]Transcription activator-like effector nucleases (TALENs) bind as a pair around a genomic site, in which a double-strand break (DSB) is introduced by a dimer of FokI nuclease domains. The use of a TALEN genome-editing system to rapidly and efficiently generate mutant alleles of 15 different genes in human pluripotent stem cells (hPSCs) as a means of performing rigorous disease modeling was recently reported (Ding et al., Cell Stem Cell 12:238-251 (2013)); the proportions of clones bearing at least one mutant allele ranged from 2%-34%.

[0290]As described below, the relative efficacies of CRISPRs and TALENs targeting the same genomic sites in the same hPSC lines was assessed with the use of the same delivery platform described previously (Ding et al., Cell Stem Cell 12:238-251 (2013)). In the TALEN genome-editing system, the CAG promoter was used to co-translate (via a viral 2A peptide) each TALEN with green fluorescent protein (GFP) or red fluorescent protein (RFP). For CRISPRs, ...

example 2

Targeting of Clinically Relevant Genes in Primary Somatic Cells

[0296]Work described herein shows for the first time that the CRISPR / Cas9 system can be used to edit the genome of somatic cells (e.g., primary) with high efficiency by using a double guide strategy. The inventors posit that this work will help bring genome editing in clinically relevant primary cells into reality.

[0297]The advent of genome editing tools that allow one to target any desired genomic site has greatly advanced the investigation of human biology and disease. In particular, the CRISPR / Cas9 system has become the gold standard in targeted genome editing technology, due to its flexibility and high efficacy. This system is constituted by the Cas9 nuclease from the microbial type II CRISPR / Cas system, which is targeted to specific genomic loci by a 20-nucleotide region in a synthetic guide RNA molecule. Similar to other targeted nucleases (ZFNs and TALENs), Cas9 induces double strand breaks (DSBs) that are repaire...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed herein are methods, compositions, and kits for high efficiency, site-specific genomic editing of cells.

Description

RELATED APPLICATIONS[0001]This application is a divisional application of U.S. application Ser. No. 14 / 485,288, filed on Sep. 12, 2014, which is a continuation of PCT Application No. PCT / US2014 / 033082, filed Apr. 4, 2014, which claims the benefit of U.S. Provisional Application Ser. No. 61 / 808,594, filed Apr. 4, 2013, the teachings of which are incorporated herein by reference in their entirety.GOVERNMENT SUPPORT[0002]This invention was made with government support under HL107440, R01-HL118744, R00-HL098364 and R01-DK095384 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]Clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas) systems are a new class of genome-editing tools that target desired genomic sites in mammalian cells. Recently published type II CRISPR / Cas systems use Cas9 nuclease that is targeted to a genomic site by complexing with a synthetic guide RNA that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/63C12N15/90
CPCC12N15/63C12N15/907A61K48/00A61P31/00A61P31/18A61P35/00A61P43/00C12N5/0606
Inventor MUSUNURU, KIRANCOWAN, CHAD A.ROSSI, DERRICK J.
Owner PRESIDENT & FELLOWS OF HARVARD COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap